TY - JOUR
T1 - Tamponade in surgery for retinal detachment associated with proliferative vitreoretinopathy
AU - Schwartz, Stephen G.
AU - Flynn, Harry W.
AU - Lee, Wen Hsiang
AU - Wang, Xue
N1 - Funding Information:
• Partially supported by NIH center grant P30-EY014801, USA. • Unrestricted grant to the University of Miami from Research to Prevent Blindness, USA. • National Eye Institute, National Institutes of Health, USA.
Funding Information:
Richard Wormald (Co-ordinating Editor for CEVG) acknowledges financial support for his CEVG research sessions from the Department of Health through the award made by the National Institute for Health Research to Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology for a Specialist Biomedical Research Centre for Ophthalmology. The views expressed in this publication are those of the authors and not necessarily those of the Department of Health.
Funding Information:
Xue Wang is supported by the Cochrane Eyes and Vision Group US Project through the National Eye Institute, Grant 1 U01 EY020522
Funding Information:
We acknowledge Iris Gordon, the Trials Search Co-ordinators for the Cochrane Eyes and Vision Group (CEVG), for designing and conducting the electronic searches. We acknowledge support provided by the CEVG US Project, which is funded by Grant 1 U01 EY020522-01, National Eye Institute, National Institutes of Health. We also acknowledge Peter Gehlbach, Barbara Hawkins, Kate Henshaw and Tianjing Li for their comments on the protocol version of this review (Schwartz 2006). We acknowledge Ann-Margret Ervin (AE) and Elizabeth Ssemanda (ES) for their contribution to the previous published version of the review (Schwartz 2009), and Michael Marrone for his assistance in data extraction during the update of this review.
PY - 2014/2/14
Y1 - 2014/2/14
N2 - Retinal detachment (RD) with proliferative vitreoretinopathy (PVR) often requires surgery to restore normal anatomy and to stabilize or were not specified. Of the 94 participants, four died, 26 had recurrent retinal detachment, 22 developed glaucoma, four developed a cataract, and two had capsular fibrosis.All three trials employed adequate methods for random sequence generation and allocation concealment. None of the trials employed masking of participants and surgeons, and only the third trial masked outcome assessors. The first trial had a large portion of participants excluded from the final analyses, while the other two trials were at low risk of attrition bias. All trials appear to be free of reporting bias. The first two trials were funded by the National Eye Institute, and the third trial was funded by the German Research Foundation. The use of either perfluropropane or standard silicone oil appears reasonable for most patients with RD associated with PVR. Because there do not appear to be any major differences in outcomes between the two agents, the choice of a tamponade agent should be individualized for each patient. Heavy silicone oil, which is not available for routine clinical use in the USA, has not demonstrated evidence of superiority over standard silicone oil.
AB - Retinal detachment (RD) with proliferative vitreoretinopathy (PVR) often requires surgery to restore normal anatomy and to stabilize or were not specified. Of the 94 participants, four died, 26 had recurrent retinal detachment, 22 developed glaucoma, four developed a cataract, and two had capsular fibrosis.All three trials employed adequate methods for random sequence generation and allocation concealment. None of the trials employed masking of participants and surgeons, and only the third trial masked outcome assessors. The first trial had a large portion of participants excluded from the final analyses, while the other two trials were at low risk of attrition bias. All trials appear to be free of reporting bias. The first two trials were funded by the National Eye Institute, and the third trial was funded by the German Research Foundation. The use of either perfluropropane or standard silicone oil appears reasonable for most patients with RD associated with PVR. Because there do not appear to be any major differences in outcomes between the two agents, the choice of a tamponade agent should be individualized for each patient. Heavy silicone oil, which is not available for routine clinical use in the USA, has not demonstrated evidence of superiority over standard silicone oil.
UR - http://www.scopus.com/inward/record.url?scp=84907662242&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84907662242&partnerID=8YFLogxK
U2 - 10.1002/14651858.CD006126.pub3
DO - 10.1002/14651858.CD006126.pub3
M3 - Review article
C2 - 24532038
AN - SCOPUS:84907662242
VL - 2014
JO - The Cochrane database of systematic reviews
JF - The Cochrane database of systematic reviews
SN - 1361-6137
IS - 2
M1 - CD006126
ER -